Drug-companion features turn wearable, app and nutrition companies into pharma partners, and partners inherit pharma's rules. The first time a member describes a side effect in a co-branded live session, a wellness company is holding information its partner is obliged to report within days.
The Adelo teamAdelo Insights
Published 3 November 2026
An Adelo Insights essay on health tech and the expert voice
In May 2026, Oura launched GLP-1 Insights with its Ring 5: members can log doses and schedules, record side effects and weight, and upload blood biomarkers, alongside sleep and activity data. The same launch put licensed providers inside the app through Counsel Health and added a ResMed route for members with breathing disturbances at night.1 A month earlier, WHOOP had closed a $575 million Series G with Abbott as a strategic investor.2 Nutrition apps, coaching programs and protein brands are building products around people on these drugs too. Consumer health is no longer just adjacent to medicine; in programs like these it sits alongside the prescription.
1
Partners inherit the rules
The pharmacovigilance rules are written for the company that holds the marketing authorization, and they are strict. In the EU, a serious suspected adverse reaction must be submitted to the regulator no later than 15 calendar days after it first reaches the company, and that includes reaching a medical representative or a contractor.3 The same guideline says the company should have explicit procedures and detailed agreements with any organization it works with, specifying how safety information is exchanged, with what timelines and whose responsibility.3
Read that from the consumer company's side. The moment you run a GLP-1 program with a drug company, you are the organization in that sentence. Your member chat, your live Q&A, your side-effect log and your expert sessions are places where a report can arrive, and your partner's clock starts when it reaches you. The guideline also treats reports from organized programs such as patient support programs and surveys as solicited, handled like study reports rather than spontaneous ones.3 A co-branded member program is likely to be read that way, which argues for agreeing the process before the first session rather than for avoiding the partnership.
Fig. 1The clock
Fifteen days from a member's mention to the regulator
Adelo Insights · based on EU GVP Module VI · confirm obligations with a regulatory adviser
The day your health app signs a pharma deal, your Q&A box becomes a safety system.
Adelo Insights · Part 6
2
What WeightWatchers learned in public
WeightWatchers shows how fast the ground moves. For decades it sold meetings, points and a community. In 2023 it bought Sequence, a telehealth platform through which people can be prescribed GLP-1 weight-loss drugs, and put the drugs at the center of its strategy. In May 2025 it filed for Chapter 11 through a prepackaged restructuring that eliminated $1.15 billion of debt, while telling members their service would not be disrupted.4
The lesson for wearable and app companies is about speed. A consumer wellness brand can become a business that sits next to a prescription within a couple of years, and the rules, the partners and the questions members ask all change with it. The companies that already run expert sessions with moderation, consent and safety capture will make that move far more easily than the ones that have to build it after the first deal.
3
What to build before the first deal
What the partner's safety team will ask
What you need to be able to show
How do you capture a side effect mentioned by a member?
Flagging in live sessions and chat, AI-assisted and by hosts, with the four details a valid report needs
How fast does it reach us?
A same-day hand-over route and a record of when each flag was raised and passed on
Who sees member data, and did members agree?
Consent recorded before entry, linked to the session, and access controls
Can we audit what was said?
Recording, transcript and an append-only log of flags, reviews and exports
Who answers medical questions on your sessions?
A moderation rule: questions about doses and symptoms are held and answered by a qualified person
Write the safety agreement first. Timelines, responsibilities and the hand-over route, as the guideline requires. It will shape the product.
Treat live sessions and chat as sources. That is where members say the honest thing.
Brief every expert on what to do when a member describes a symptom: capture, don't diagnose, hand over.
Keep the record ready to export. A safety team that can see consent, transcript and flags in one place approves faster.
4
Why a safety process helps win partners
Most consumer health companies will see this as a cost, and the sharper ones will see it as what wins the deal. A pharma partner's procurement and safety teams have to approve every vendor that touches a program. The partner that can show consent, moderated participation, adverse event capture and an audit trail on day one gets approved in a week instead of a quarter. And the bigger prize is a new role: the place where drug makers and clinicians help patients with the lifestyle side of a therapy, from sleep and activity to nutrition and side effects, explained by experts and governed properly.
Frequently asked questions
What does a pharma partnership mean for a health app?
The app takes on pharma's safety rules. Anything a user says about a side effect of the partner's drug, including in chat or a live Q&A, may be an adverse event the partner has to report within strict timelines. Build consent, moderation and safety capture before the first deal, because the partner's safety team will ask to see them.
Why do GLP-1 features matter for wearables?
Features such as Oura's GLP-1 Insights let members log doses, side effects and weight alongside sleep and activity. That data, and the conversations around it, sit much closer to a medicine than a step count does, and they make the wearable an attractive partner for the companies that make the drugs.
Do health tech companies have to report adverse events?
The legal duty sits with the marketing authorization holder, the pharma company. But EU good pharmacovigilance practice requires that company to have explicit procedures and detailed agreements with any organization it works with, so that suspected adverse reactions are collected and passed on in time. In a partnership, that organization is the wearable, app or nutrition company.
How fast do adverse events have to be reported?
In the EU, a serious case must be submitted no later than 15 calendar days after it first reaches the company or anyone working for it, including contractors. The clock does not wait for a partner to notice.
Is a co-branded live session a solicited or spontaneous source?
Reports from organized programs such as patient support programs and surveys are treated as solicited and handled like study reports. A co-branded member program run with a pharma partner is likely to fall into that category, which is one more reason to agree the process before the first session.
How can a health tech company prepare for pharma deals?
Build consent, moderated participation, adverse event capture and an audit trail before the first deal, so a partner's procurement and safety teams can approve quickly and the first side effect mentioned in a live session has somewhere to go.
Adelo Insights are written by the Adelo team, the professional video event platform for health. They draw on the sessions pharma, agency and consumer health teams run on Adelo every week, and on the research cited in each essay.
Adelo Insights · Health tech and the expert voice
